Aubert J, Dore B, Irani J, Bon D
Service d'Urologie, CHU de Poitiers.
J Urol (Paris). 1990;96(8):431-5.
On the basis of a retrospective series of 74 patients with adenocarcinoma of the prostate, the authors study the survival of these patients according to the clinical stage of the lesion when treated with cyproterone acetate. Biologically speaking, the authors have studied the evolution of the blood testosterone level, as well as of PSA and PAPs. Their conclusion is that the PSA is an excellent indicator of the efficacy of the cyproterone acetate treatment. Its fast decrease proves treatment efficacy, while a new rise indicates the resumption of evolution of the neoplastic process and must lead to change the therapeutic approach.
基于对74例前列腺腺癌患者的回顾性研究系列，作者根据醋酸环丙孕酮治疗时病变的临床分期研究了这些患者的生存率。从生物学角度讲，作者研究了血液睾酮水平以及前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAPs）的变化情况。他们的结论是，PSA是醋酸环丙孕酮治疗效果的极佳指标。其快速下降证明治疗有效，而再次升高则表明肿瘤进程重新进展，必须导致治疗方法的改变。
